Payment overview · 2025
General Payments
$110.49
6 reported records · 2 companies
Healthcare provider profile · identity verified
Emily Huff, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · PADUCAH, KY · NPI 1487277000
Verified facts
What the public records show
CMS Open Payments records show Emily Huff, APRN received $110.49 in general payments during 2025 across 6 reported records.
ABBVIE INC. accounted for 78.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nurtec Odt.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Vraylar by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $86.45 | 78.2% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.04 | 21.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $110.49 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $86.45 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $36.48 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $24.04 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $24.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
67 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 255 | 72 |
| Levothyroxine Sodium | Levothyroxine Sodium | 241 | 62 |
| Buspirone Hcl | Buspirone Hcl | 167 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 164 | 18 |
| Gabapentin | Gabapentin | 157 | 28 |
| Amlodipine Besylate | Amlodipine Besylate | 152 | 44 |
| Omeprazole | Omeprazole | 149 | 47 |
| Lisinopril | Lisinopril | 148 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 145 | 34 |
| Losartan Potassium | Losartan Potassium | 144 | 43 |
| Simvastatin | Simvastatin | 121 | 32 |
| Montelukast Sodium | Montelukast Sodium | 120 | 37 |
| Metformin Hcl | Metformin Hcl | 110 | 31 |
| Meloxicam | Meloxicam | 109 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 109 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 108 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 106 | 31 |
| Furosemide | Furosemide | 104 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 99 | 29 |
| Mounjaro | Tirzepatide | 94 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 93 | 18 |
| Farxiga | Dapagliflozin Propanediol | 92 | 15 |
| Baclofen | Baclofen | 84 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 71 | 22 |
| Eliquis | Apixaban | 67 | 17 |
| Fenofibrate | Fenofibrate | 67 | 20 |
| Sertraline Hcl | Sertraline Hcl | 58 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 15 |
| Potassium Chloride | Potassium Chloride | 50 | 12 |
| Trazodone Hcl | Trazodone Hcl | 48 | 13 |
| Jardiance | Empagliflozin | 47 | 13 |
| Celecoxib | Celecoxib | 46 | 14 |
| Tramadol Hcl | Tramadol Hcl | 46 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 45 | 11 |
| Alprazolam | Alprazolam | 44 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | suppressed |
| Carvedilol | Carvedilol | 41 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 40 | 13 |
| Ramipril | Ramipril | 40 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 12 |
| Allopurinol | Allopurinol | 37 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 37 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 34 |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Ozempic | Semaglutide | 34 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Estradiol | Estradiol | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 31 | 11 |
| Cefdinir | Cefdinir | 30 | 25 |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 30 | suppressed |
| Famotidine | Famotidine | 30 | 12 |
| Spironolactone | Spironolactone | 29 | suppressed |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 25 | 12 |
| Prednisone | Prednisone | 25 | 15 |
| Lovastatin | Lovastatin | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 15 |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 17 |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 16 |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Nystatin | Nystatin | 17 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Vraylar | Cariprazine Hcl | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 15 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $110.49 · 6 records | ABBVIE INC. | NURTEC ODT, QULIPTA, UBRELVY, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nurtec Odt play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error